Abstract
(Abstracted from Urogynecology 2024;30:467–475 In 2013, the American Urogynecologic Society (AUGS) Board of Directors distributed a “Position Statement on Restriction of Surgical Options for Pelvic Floor Disorders” in response to limitations instituted by the US Food and Drug Administration (FDA) on the use of transvaginal mesh (TVM) for pelvic organ prolapse (POP) due to concerns about safety and effectiveness. This article is an update to that statement informed by additional clinical data, decisions from the FDA, and relevant guidelines regarding surgical mesh.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
